Alveron Pharma
Alveron Pharma is a clinical-stage company dedicated to developing innovative treatments for intracranial haemorrhage (ICH) and related conditions. Their mission is to create rapid, universal, and effective therapies that significantly improve patient outcomes, especially in emergency situations involving anticoagulants and platelet inhibitors. The company's vision is to address severe unmet medical needs in stroke treatment through groundbreaking drug development and advanced diagnostic technologies.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Synthetic cyclodextrin-based procoagulant drug candidate
A synthetic, small-molecule procoagulant being developed as a ready-to-use intravenous therapy to reverse anticoagulant and certain antiplatelet effects rapidly, with the aim of reducing haematoma expansion and improving outcomes in intracranial haemorrhage and other life-threatening bleeds.
Synthetic cyclodextrin-based procoagulant drug candidate
A synthetic, small-molecule procoagulant being developed as a ready-to-use intravenous therapy to reverse anticoagulant and certain antiplatelet effects rapidly, with the aim of reducing haematoma expansion and improving outcomes in intracranial haemorrhage and other life-threatening bleeds.
Expertise Areas
- Intracranial haemorrhage therapeutics
- Universal anticoagulant and antiplatelet reversal
- Preclinical efficacy and safety evaluation
- Early-phase clinical development (Phase I)
Key Technologies
- Cyclodextrin-based small-molecule procoagulants
- Universal anticoagulant/antiplatelet reversal mechanism (downstream clotting factor targeting)
- Intracranial haemorrhage rodent models
- Standardized bleeding/haemostasis assays
News & Updates
Alveron Pharma announced the closing of a €5.0 million Series Seed extension financing to accelerate the development of its drug OKL-1111 for intracranial haemorrhage.
The company announced the completion of a Phase 1 clinical study for OKL-1111, demonstrating safety and pharmacodynamic effects in healthy volunteers.
Alveron Pharma announced the closing of a €5.0 million Series Seed extension financing to accelerate the development of its drug OKL-1111 for intracranial haemorrhage.
The company announced the completion of a Phase 1 clinical study for OKL-1111, demonstrating safety and pharmacodynamic effects in healthy volunteers.